Key result
Growth hormone reduces body fat, improves insulin sensitivity, and lowers diastolic BP in abdominally obese men.
Why the study?
There are striking similarities between metabolic syndrome and untreated adult GH deficiency, including abdominal obesity and insulin resistance, motivating investigation of GH treatment effects.
Does growth hormone treatment improve metabolic parameters in middle-aged men with abdominal obesity and patients with heart failure?
RCT
Double-blind
Randomized
Does growth hormone treatment improve metabolic parameters in middle-aged men with abdominal obesity and patients with heart failure?
Answers are grounded in this paper and cite their sources.
Growth hormone treatment may improve metabolic syndrome parameters such as visceral adiposity and insulin resistance, and shows potential as an adjunctive therapy in congestive heart failure.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bengtsson et al. (1998) conducted an RCT in Abdominal/visceral obesity. Growth Hormone (GH) vs. Placebo was evaluated on Total body fat, abdominal subcutaneous and visceral adipose tissue. Nine months of growth hormone treatment in middle-aged men with abdominal obesity reduced total body fat, improved insulin sensitivity, and decreased diastolic blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: